Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
Lenvatinib plus pembrolizumab has already been shown to improve survival [...]
NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has [...]
ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer
The phase 2 KEYNOTE-B61 study was presented at the recent [...]
ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer
Results from the phase 3 CLEAR studywere presented at the [...]
Health-related quality of life with lenvatinib in combination with everolimus
Maintaining good health-related quality of life is important for all [...]
Quality of life on lenvatinib plus pembrolizumab combination
In this study, the health-related quality of life (HRQoL) of [...]
Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib
In this video, Dr Bradley McGregor from the Dana-Farber Cancer [...]
FDA approves pembrolizumab plus lenvatinib combination for advanced kidney cancer
The US Food and Drug Administration (FDA) has approved the [...]
Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer
Results from a phase Ib/II study looking at lenvatinib plus [...]
ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer
Results from the phase 3 CLEAR study were presented at [...]
